ArticleOphthalmology. Retina2025
Risk of Adverse Systemic Events in Retinal Vein Occlusion.
Article in Ophthalmology. Retina, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of neovascular glaucoma with increased mortality and cardiovascular risk: a multicenter propensity-matched study.Scientific reports · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeConflicting data exists on whether central and branch retinal vein occlusion (CRVO and BRVO) are linked to systemic adverse events. This study examines this association using the TriNetX US Collaborative Network, encompassing >110 million patients.
designRetrospective population-based cohort design. SUBJECTS AND CONTROLS: Central and branch retinal vein occlusion cohorts were compared with control cataract cohorts and between high and low-intensity treatment defined by ≥10 compared with ≤5 anti-VEGF injections.
methodsThis study used deidentified data from a national database (2006-2024), using International Classification of Diseases,10th Revision, codes for CRVO and BRVO. Patients were propensity score matched on demographics, medications, and comorbidities. Risk ratios (RRs) were generated for systemic events in patients with CRVO and BRVO compared with controls and between patients with high and low-intensity treatment.
main outcome measuresRisk ratios (RRs) and 95% confidence intervals (CIs) of death, myocardial infarction (MI), hemorrhagic stroke, ischemic stroke, and carotid disease.
resultsCentral retinal vein occlusion was associated with increased risk of death (RR, 1.30; 95% CI, 1.26-1.35), MI (RR, 1.24; 95% CI, 1.16-1.32), hemorrhagic stroke (RR, 1.35; 95% CI, 1.21-1.51), ischemic stroke (RR, 1.49; 95% CI, 1.4-1.59), and carotid disease (RR, 1.69; 95% CI, 1.59-1.79). Branch retinal vein occlusion was associated with increased risk of death (RR, 1.27; 95% CI, 1.23-1.32), MI (RR, 1.39; 95% CI, 1.30-1.49), hemorrhagic stroke (RR, 1.57; 95% CI, 1.41-1.75), ischemic stroke (RR, 1.66; 95% CI, 1.56-1.77), and carotid disease (RR, 1.67; 95% CI, 1.57-1.77). Central retinal vein occlusion with high-intensity treatment was associated with increased risk of MI (RR, 1.47; 95% CI, 1.12-1.93) compared with low-intensity CRVO treatment, but there were no significant differences in risk of death (RR, 0.98; 95% CI, 0.86-1.11), hemorrhagic stroke (RR, 1.00; 95% CI, 0.63-1.58), ischemic stroke (RR, 1.31; 95% CI, 1.03-1.66), or carotid disease (RR, 1.34; 95% CI, 1.06-1.70). For BRVO with high compared with low-intensity treatment, no significant differences in rates of death (RR, 1.12; 95% CI, 0.96-1.31), MI (RR, 1.30; 95% CI, 0.93-1.81), hemorrhagic stroke (RR, 0.96; 95% CI, 0.60-1.53), ischemic stroke (RR, 1.05; 95% CI, 0.80-1.38), or carotid disease (RR, 1.17; 95% CI, 0.85-1.60) were identified.
conclusionsCentral and branch retinal vein occlusion are associated with increased risk of death, MI, hemorrhagic stroke, ischemic stroke, and carotid disease. High-intensity treatment of CRVO may be associated with increased risk of MI. These results from this data set demonstrate the importance of systemic evaluation after retinal vein occlusion. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.